Company News

ReflectionBio – By Patients, For Patients ^®

Company News

Publication: Evaluating precision medicine approaches for gene therapy in patient-specific cellular models of Bietti crystalline dystrophy

Publication: An In-Depth Single-Gene Worldwide Carrier Frequency and Genetic Prevalence Analysis of CYP4V2 as the Cause of Bietti Crystalline Dystrophy

ReflectionBio joins forces with patient organization Invincible Vision ahead of World Rare Disease Day for Bietti’s Crystalline Dystrophy (BCD)

SAN FRANCISCO & HONG KONG–(BUSINESS WIRE)–Today, Invincible Vision and ReflectionBio^® are launching their inaugural awareness and fundraising campaign, BY PATIENTS, FOR PATIENTS ™, for Bietti’s Crystalline Dystrophy (BCD).

Rare Disease Patient CEO Joins “Orphan Drug Development Guidebook” Task Force

Richard Yang, Founder & CEO of ReflectionBio and a rare disease patient, was invited to join the newly formed “Orphan Drug Development Guidebook” Task Force of International Rare Diseases Research Consortium (IRDiRC).

Patient-Driven Gene Therapy Company ReflectionBio^® Receives Orphan Drug Designation From U.S. FDA For the Treatment of Bietti’s Crystalline Dystrophy (BCD).

HONG KONG & NEW YORK–(BUSINESS WIRE)–Reflection Biotechnologies Limited (“ReflectionBio”), a gene therapy company committed to the research and development of life-changing treatments for rare diseases, today announced that the U.S.